A detailed history of M&G PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, M&G PLC holds 193,163 shares of BGNE stock, worth $43.8 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
193,163
Previous 173,075 11.61%
Holding current value
$43.8 Million
Previous $38.9 Billion 8.23%
% of portfolio
0.22%
Previous 0.14%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$174.72 - $246.04 $3.51 Million - $4.94 Million
20,088 Added 11.61%
193,163 $35.7 Billion
Q3 2024

Oct 31, 2024

SELL
$143.93 - $224.51 $964,906 - $1.51 Million
-6,704 Reduced 3.73%
173,075 $38.9 Billion
Q2 2024

Jul 16, 2024

SELL
$129.52 - $174.32 $1.33 Million - $1.79 Million
-10,277 Reduced 5.41%
179,779 $25.7 Billion
Q1 2024

May 10, 2024

BUY
$141.8 - $181.47 $26.9 Million - $34.5 Million
190,056 New
190,056 $29.6 Billion

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track M&G PLC Portfolio

Follow M&G PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&G PLC, based on Form 13F filings with the SEC.

News

Stay updated on M&G PLC with notifications on news.